(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 25 March 2004 (25.03.2004)

PCT

(10) International Publication Number WO 2004/024728 A3

- (51) International Patent Classification⁷: C07D 471/04, A61K 31/437, A61P 29/00, 11/00 // (C07D 471/04, 231:00, 221:00)
- (21) International Application Number:

PCT/EP2003/011814

(22) International Filing Date:

12 September 2003 (12.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:


0221455.9	16 September 2002 (16.09.2002)	GB
0230045.7	23 December 2002 (23.12.2002)	GB
0306595.0	21 March 2003 (21.03.2003)	GB
0308017.3	7 April 2003 (07.04.2003)	GB
0319708.4	21 August 2003 (21.08.2003)	GB
0321074.7	9 September 2003 (09.09.2003)	GB

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ALLEN, David, George [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). COE, Diane, Mary [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). COOK, Caroline, Mary [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). DOWLE, Michael, Dennis [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). EDLIN, Christopher, David [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HAMBLIN, Julie, Nicole [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). JOHNSON, Martin, Redpath [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). JONES, Paul, Spencer

[Continued on next page]

(54) Title: PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS





(57) Abstract: The invention relates to compound formula (I) or a salt thereof: C1-4alkyl, wherein:R1 is C1-3fluoroalkyl, -CH2CH2OH -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalkyl optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee): ; and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease

(COPD), asthma, or allergic rhinitis.



I TREAT BUILDING AN BUILDING BUILD BUILD BUILD BUILD AND AN BUILDING BUILDING BUILDING BUILDING BUILDING BUILD

[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). KNOWLES, Richard, Graham [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). LINDVALL, Mika, Kristian [FI/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). MITCHELL, Charlotte, Jane [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). REDGRAVE, Alison, Judith [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). TRIVEDI, Naimisha [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WARD, Peter [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

- (74) Agent: WATERS, David, Martin; GlaxoSmithKline, CN925.1, Corporate Intellectual Property, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

- GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 21 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

onal Application No PC17EP 03/11814

a. classification of subject matter IPC 7 C07D471/04 A61k A61K31/437 A61P11/00 A61P29/00 //(C07D471/04,231:00,221:00) According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7D A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. 1,56,61 WO OO 15222 A (SQUIBB BRISTOL MYERS CO) Α 23 March 2000 (2000-03-23) claims 1,9 Further documents are listed in the continuation of box C. Patent family members are listed in annex. ° Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 03/03/2004 19 February 2004

Authorized officer


Alfaro Faus, I

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

International Application No PC1/EP 03/11814

Citation of document, with indication,where appropriate, of the relevant passages A DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DALY, JOHN W. ET AL: "1-Methyl-4-substituted-1H-pyrazolo'3,4-b! pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors" retrieved from STN Database accession no. 122:45666 XP002270929 cited in the application abstract & MEDICINAL CHEMISTRY RESEARCH (1994), 4(5), 293-306,
A DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DALY, JOHN W. ET AL: "1-Methyl-4-substituted-1H-pyrazolo'3,4-b! pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors" retrieved from STN Database accession no. 122:45666 XP002270929 cited in the application abstract & MEDICINAL CHEMISTRY RESEARCH (1994),
CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DALY, JOHN W. ET AL: "1-Methyl-4-substituted-1H-pyrazolo'3,4-b! pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors" retrieved from STN Database accession no. 122:45666 XP002270929 cited in the application abstract & MEDICINAL CHEMISTRY RESEARCH (1994),



Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claim 62 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the					
compounds. 2. Claims Nos.:					
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:					
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

formation on patent family members

International Application No
PCT/EP 03/11814

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0015222	A	23-03-2000	AU CA EP JP WO US	751486 B2 6143899 A 2342583 A1 1113796 A1 2002524512 T 0015222 A1 6326379 B1	15-08-2002 03-04-2000 23-03-2000 11-07-2001 06-08-2002 23-03-2000 04-12-2001